Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

ABSTRACT:

Background

A standard-of-care for locally advanced esophageal and gastroesophageal junction (GEJ) adenocarcinoma is pre-operative chemoradiation. Elevated levels of vascular endothelial growth factor (VEGF) have been associated with worse outcomes following chemoradiation and anti-VEGF therapies can potentiate radiation efficacy.

Methods

In this single-arm phase II study, we added bevacizumab to induction chemotherapy and concurrent chemoradiation with cisplatin/irinotecan for locally advanced esophageal and GEJ adenocarcinomas.

Results

Thirty-three patients were enrolled, with all evaluable. All tumors involved the GEJ and 67% were node-positive by endoscopic ultrasound (EUS) and imaging. Twenty-eight patients completed chemoradiation and 26 patients underwent surger

SUBMITTER: Ku GY 

PROVIDER: S-EPMC5177593 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature